{
  "trial_id": "NCT02448238",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "HIV-1 infection, documented by any licensed rapid HIV test or HIV enzyme or chemiluminescence immunoassay (E/CIA) test kit at any time prior to study entry and confirmed by a licensed Western blot or a second antibody test by a method other than the initial rapid HIV and/or E/CIA, or by HIV-1 antigen, or plasma HIV-1 RNA viral load.",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "No plans to initiate ART during the course of the proposed study. NOTE: Subjects who meet WHO treatment guidelines for initiating ART once enrolled should begin therapy as clinically indicated. These subjects must stop study treatment, and will be followed on study/off study treatment.",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Screening CD4+ T-cell count \u2265 350 cells/mm3 performed in a laboratory that has a Malian National Institute for Public Health and Research (INRSP) certification, or its equivalent, within 45 days prior to study entry.",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Laboratory values obtained within 45 days prior to entry as follows: Absolute neutrophil count (ANC) \u2265 1000/mm3",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Hemoglobin \u2265 10.0 g/dL",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Platelet count \u2265 50,000/mm3",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Female subjects of reproductive potential [defined as girls who have reached menarche or women who have not been post-menopausal for at least 12 consecutive months, i.e., who have had menses within the preceding 12 months, or have not undergone surgical sterilization (e.g., hysterectomy, bilateral oophorectomy, or bilateral tubal ligation)] must have a negative serum or urine pregnancy test performed within 45 days prior to entry.",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Female subjects participating in sexual activity that could lead to pregnancy must agree to use at least one of the following forms of birth control for at least 45 days prior to study entry until the final study visit:",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Malian women age => 18 years.",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Ability and willingness of subject to provide informed consent.",
      "label": "met",
      "evidence": "quote"
    }
  ],
  "exclusion": [
    {
      "criterion": "Pregnant.",
      "label": "not_met",
      "evidence": "none"
    },
    {
      "criterion": "Use of any antiretroviral agent during or within 24 weeks prior to study entry.",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "Active illicit drug or alcohol use or dependence, or conditions that, in the opinion of the site investigator, would interfere with adherence to study requirements.",
      "label": "unknown",
      "evidence": "none"
    }
  ],
  "notes": "Patient has a history of recent travel and symptoms consistent with V. cholerae infection.",
  "_meta": {
    "topic_id": "52",
    "trial_id": "NCT02448238",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}